Hemab Therapeutics Holdings, Inc. (COAG) stock analysis
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.38+0.05 (+0.13%)
Close on Nov 12, 2026Market cap $1.84BP/E –Yield –
Analysis
Not enough annual history yet
Analysis needs at least two fiscal years of reported financials for Hemab Therapeutics.
See a number that looks wrong?